{"filings":[{"id":1387916,"accession_number":"0001193125-26-292547","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-07-01T20:10:23+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates ASCO 2026 data; VMT-α-NET shows deepening responses in NETs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VMT-α-NET (212Pb for SSTR2+ NETs) shows best response deepens over time; durable disease control across doses; stable renal function in 68 patients.","VMT01 (212Pb for MC1R+ melanoma) shows preliminary anti-tumor activity at 3.0 mCi dose; well-tolerated with TEAEs in ≥10% of patients.","PSV359 (212Pb targeting FAP-ɑ) enters Phase 1/2a for advanced solid tumors with improved tumor retention.","Pipeline also includes CCK2R81 for medullary thyroid cancer and combination with immune checkpoint inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":758998,"accession_number":"0001193125-26-249594","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-06-01T10:30:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates pipeline: VMT-α-NET durable disease control; VMT01 and PSV359 progress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VMT-α-NET (SSTR2+ NET) Phase 1/2a shows durable disease control; potential registration study at current dose level.","VMT01 (MC1R melanoma) Phase 1/2a: preliminary anti-tumor activity observed at 3.0 mCi dose.","PSV359 (FAP-ɑ solid tumors) Phase 1/2a demonstrates improved tumor retention in ongoing trial.","Integrated isotope production enables direct-to-hospital delivery and regional manufacturing for supply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":696076,"accession_number":"0001193125-26-241940","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-05-27T20:20:15+00:00","items":["5.07"],"status":"ready","headline":"Perspective Therapeutics announces 2026 annual meeting voting results; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected all six director nominees: Woods, Henson, Martinez-Davis, Morich, Spoor, Williamson.","Ratified WithumSmith+Brown as independent auditor for FY2026 with 97.6M votes for.","Non-binding advisory vote favored annual say-on-pay; Board adopts 1-year frequency.","97,882,462 shares (85.85% of outstanding) represented at meeting, forming quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":590689,"accession_number":"0001193125-26-234991","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-05-21T22:02:43+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports interim clinical data from three radiopharmaceutical programs at ASCO 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VMT01 in melanoma: 2/7 confirmed responses (29%) at 3.0 mCi; 6/7 stable disease or partial response.","[212Pb]PSV359 advanced to Cohort 3 (6.0 mCi); no DLTs, grades 1-2 TEAEs only.","VMT-α-NET: deepened responses vs prior cut-offs; 10/23 (43%) Cohort 2 patients achieved response per RECIST v1.1.","All programs well-tolerated: no treatment-related discontinuations, no Grade 4/5 events across 68+ patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13131,"accession_number":"0001193125-26-216777","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-05-11T20:10:44+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports Q1 2026 net loss of $26.2M; cash raised to $271M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.2M ($0.25/share) vs. $18.2M net loss in Q1 2025; R&D spend up 50% YoY to $21.4M.","Cash, equivalents & short-term investments $271M as of Mar 31, 2026, up from $145M at Dec 31, 2025; includes $164M net from Feb 2026 offering.","Cash runway expected into late 2027 to support clinical milestones; lead program VMT-α-NET advancing to Cohort 4 and meningioma cohort.","VMT01 (melanoma) dosing cohorts closed after 10 patients treated at 3.0 mCi; PSV359 (FAP) Cohort 3 open.","Chicago manufacturing site on track to complete construction in 2026."],"consensus_eps_estimate":-0.3021,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98549,"accession_number":"0001193125-26-204161","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates VMT-α-NET Ph1/2a data and preliminary cash position","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary cash & short-term investments as of Mar 31, 2026 disclosed; unaudited, subject to final adjustments.","VMT-α-NET Phase 1/2a data show durable disease control across all doses; responses deepen over time.","Company says profile supports potential registration study at current dose level.","Manufacturing update: daily production at regional sites for ready-to-administer 212Pb products.","Expanding pipeline includes CCK2R81 targeting and other solid tumor programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98548,"accession_number":"0001193125-26-162578","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective reports 43% ORR, clean safety for [212Pb]VMT-α-NET in Phase 1/2a at AACR 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Objective response rate 43% (10/23) in Cohort 2 first half; 9 patients with deepening response since ESMO 2025.","Safety (n=64): no DLTs, no Grade 4/5 AEs, no treatment-related discontinuations, no renal complications.","18 of 25 patients (72%) progression-free in Cohorts 1 and 2 first half as of March 4, 2026 data cutoff.","Initial efficacy data from additional 23 Cohort 2 and first 8 Cohort 3 patients expected later 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98547,"accession_number":"0001193125-26-137930","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation; highlights 212Pb pipeline with Phase 1/2a data in 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Phase 1/2a data for VMT-α-NET in neuroendocrine tumors shows durable disease control and best-in-class safety profile.","VMT01 (212Pb-MC1R) for melanoma shows preliminary anti-tumor activity and tolerability; combination with checkpoint inhibitors planned.","PSV359 targeting FAP-α for solid tumors demonstrates improved tumor retention; Phase 1/2a trial ongoing.","Phase 1/2 data expected across all three clinical programs in 2026.","Proprietary Pb-based chelator and Lead-212 isotope platform designed to optimize therapeutic index."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114106,"accession_number":"0000728387-26-000003","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports FY2025 net loss $103M; lead program shows durable responses; cash ~$309M post-offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $103.1M ($1.40/sh) vs $79.3M ($1.23) in FY2024; R&D spend $84.2M (+102% YoY).","Cash $145M at Dec 31, 2025; Feb 2026 equity offering net proceeds ~$164M; runway into late 2027.","VMT-α-NET: 76% progression-free at ~13 weeks additional follow-up; 39% objective response rate in Cohort 2.","Cohort 3 cleared for more patients; all Cohort 2 expected to have ≥48 weeks follow-up by mid-2026.","$10M non-cash impairment for deprioritized preclinical asset; three clinical programs continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114105,"accession_number":"0001193125-26-035508","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics prices $175M offering of common stock and pre-funded warrants at $3.79/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$175M from 39,576,088 shares at $3.79/share and 6,598,046 pre-funded warrants at $3.789.","Offering closed Feb 3, 2026; net proceeds to fund clinical development, manufacturing, and general corp purposes.","Underwriters include Piper Sandler, UBS, Oppenheimer, Truist, and LifeSci Capital.","Participation from Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital (Citadel), and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114104,"accession_number":"0001193125-26-032706","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation with estimated cash balance and pipeline milestones","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Estimated cash, cash equivalents and short-term investments as of Dec 31, 2025 disclosed (amount not specified in filing).","Phase 1/2 data expected across all three clinical programs during 2026.","VMT-α-NET shows durable disease control and best-in-class safety profile in neuroendocrine tumors.","VMT01 exhibits preliminary anti-tumor activity at lower doses in melanoma.","PSV359 targeting FAP-α for solid tumors is ongoing in Phase 1/2a trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114103,"accession_number":"0001193125-26-012259","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation with pipeline progress and 2026 data expectations","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Lead programs VMT-α-NET (SSTR2+ NETs), VMT01 (MC1R melanoma), PSV359 (FAP-α) all in Phase 1/2a trials.","Proprietary 212Pb-based radioligand platform and chelator designed for broader use; manufacturing underway.","Phase 1/2 data expected across all three clinical programs in 2026.","Preliminary anti-tumor activity observed for VMT01 at lower dose; well-tolerated safety profile.","VMT-α-NET shows compelling anti-tumor activity and best-in-class safety; potential registration study at current dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114102,"accession_number":"0001193125-26-009846","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics provides VMT-α-NET and pipeline updates; 76% progression-free in NET trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VMT-α-NET Cohort 2: 19/25 pts (76%) progression-free at median ~13 wks additional follow-up vs ESMO 2025; 9/23 (39%) had RECIST response.","Safety in 56 pts: no DLTs, no treatment-related discontinuations; Grade 3+ AEs in 37.5%, one transient Grade 4 lymphopenia.","Cohort 3 (6.0 mCi) cleared by SMC after 8-patient DLT review; 9 patients treated as of Dec 31, 2025.","VMT01 melanoma: 9 patients dosed at 3.0 mCi (5 with nivolumab, 4 monotherapy) as of Dec 31; data submission planned after 24-week follow-up.","PSV359 FAP-targeting trial: 5 patients dosed across Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) with site activations underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114101,"accession_number":"0001193125-26-008277","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports 39% ORR in Cohort 2 of [212Pb]VMT-α-NET trial; safety cleared at 6.0 mCi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated interim data from Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-expressing NETs at ASCO-GI.","Objective response rate of 39% (9/23) in Cohort 2 per RECIST v1.1; 8 confirmed, 1 pending.","76% (19/25) of evaluable patients without progression and alive; deepening of best response seen in 7 patients.","DLT assessment completed for Cohort 3 (6.0 mCi); cleared to enroll more; one additional patient already treated.","No DLTs, treatment-related discontinuations, or serious renal complications across 56 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130483,"accession_number":"0001193125-25-303895","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation; highlights pipeline progress","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Updated presentation covers [212Pb]VMT-α-NET Phase 1/2a for NETs and [212Pb]VMT01 for melanoma.","Claims compelling anti-tumor activity, durable disease control, and best-in-class safety for NET trial.","Presentation notes upcoming data milestones but no specific dates or new financial guidance.","Pipeline includes PSV359 targeting FAP-α; supply chain with on-demand regional sites.","No material changes to business or financials disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130482,"accession_number":"0001193125-25-274318","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports Q3 2025 net loss of $26.0M; cash $174M into late 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.0M ($0.35/sh) vs $15.1M ($0.21) in Q3 2024; R&D spend $20.3M up 69% YoY.","Cash $174M as of Sep 30, 2025, down from $227M at Dec 31, 2024; runway into late 2026.","Clinical: VMT-α-NET cohort 3 opened June 2025, 8 patients enrolled; favorable safety in 55 patients.","VMT01 melanoma: 5 patients dosed at 3.0 mCi (monotherapy or +nivolumab) as of Oct 31, 2025.","PSV359 FAP-α therapy: 3 patients treated as of Oct 31, 2025."],"consensus_eps_estimate":-0.3328,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130481,"accession_number":"0001193125-25-268124","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation; details not available from excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing on Nov 6, 2025 indicates presentation update, but provided exhibit excerpt is truncated.","No specific pipeline, financial, or guidance changes can be extracted from the available text.","Investors should review the full corporate presentation for any material updates.","Ticker CATX (NYSE American) unchanged; no event date or figures disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130480,"accession_number":"0001193125-25-262636","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Perspective Therapeutics amends CEO, CAO, CMO employment agreements with enhanced CIC severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Thijs Spoor base salary $680,000; CAO Jonathan Hunt $451,500; CMO Markus Puhlmann $516,700.","CIC severance: Spoor receives 18 months salary + 1.5x target bonus; Hunt and Puhlmann 12 months salary + 1x target bonus.","Equity awards vest fully upon qualifying termination within CIC protection period (3 months before to 12 months after).","Amended agreements replace 2023 versions; other terms remain unchanged per proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130479,"accession_number":"0001193125-25-242912","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports 44% ORR in [212Pb]VMT-α-NET trial; cash $174.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2a data: 44% objective response rate (7/16) in Cohort 2 patients with SSTR2+ all tumors at median 41-week follow-up.","No dose-limiting toxicities, treatment-related discontinuations, or Grade 4/5 adverse events observed across 55 treated patients.","14 of 16 Cohort 2 patients with SSTR2+ all tumors remain progression-free and on study (87.5%).","Preliminary cash, cash equivalents and short-term investments ~$174.1M as of Sep 30, 2025, funding operations into late 2026.","Initial efficacy data for additional 31 patients expected in 2026; company plans registration study based on emerging profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130478,"accession_number":"0001193125-25-225858","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics files routine corporate presentation update; no material new disclosure","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation shows [212Pb]VMT-α-NET Phase 1/2a data in NET with confirmed partial response in patient 103-105.","Tolerability data: mild, transient creatinine increase; no unexpected safety signals.","Pipeline includes [212Pb]VMT01 for melanoma and [212Pb]PSV359 targeting FAP-α in trials.","Pre-targeting platform and supply chain manufacturing infrastructure also highlighted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147037,"accession_number":"0000728387-25-000013","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perspective Therapeutics appoints Joel Sendek as CFO, replacing Juan Graham","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Sept 4, 2025; Sendek brings over 30 years of biotech finance and equity research experience.","Sendek previously served as CFO at four biotech firms and raised over $2.5B in capital.","Compensation: $500k base salary, 40% target bonus, and 600,000 stock options vesting over 4 years.","No family relationships or material transactions with Sendek were reported.","Juan Graham will receive severance per his existing employment agreement upon signing a separation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147036,"accession_number":"0000728387-25-000010","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perspective Therapeutics appoints Maya Martinez-Davis, GSK US President, to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 6; Martinez-Davis appointed as independent director effective Sept 3, 2025.","She serves on Compensation and Nominations Committees; receives $60K annual cash retainer plus 75K options (max $450K fair value) vesting over 36 months.","Martinez-Davis brings 20+ years pharma experience; currently leads GSK's US commercial business since 2019.","Her prior roles include President of biopharma Latin America at Merck KGaA and senior roles at Pfizer and Mirati board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147035,"accession_number":"0000728387-25-000006","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing reports updated corporate presentation as Exhibit 99.1, but no specific new data or milestones are mentioned.","Presentation covers 212Pb radiopharmaceutical pipeline for neuroendocrine tumors and melanoma, and manufacturing supply chain.","No financial results, guidance changes, or regulatory events are presented in the filing or exhibit.","Updates appear to be routine corporate slides without substantive new disclosures for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147034,"accession_number":"0000950170-25-107609","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics Q2 net loss $21.5M, EPS -$0.29; cash $192M; VMT-α-NET Cohort 3 opened","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.5M ($0.29 per share) vs $11.7M ($0.18) in Q2 2024; operating expenses rose 65%.","Cash, cash equivalents & short-term investments $192M as of June 30, sufficient into late 2026.","R&D expenses $16.6M (+79% YoY) driven by clinical site activities and drug product costs.","FDA alignment obtained to open Cohort 3 (6.0 mCi) for [212Pb]VMT-α-NET; two patients dosed as of July 31.","VMT01 melanoma program: combination with nivolumab cohort opened; five monotherapy patients treated."],"consensus_eps_estimate":-0.3079,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147033,"accession_number":"0000950170-25-101414","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation filed August 1, 2025; no new clinical data or financial guidance disclosed.","Pipeline includes [212Pb]VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-α.","Presentation notes sustained anti-tumor activity and tolerability for NET trial; no quantitative updates.","Pre-targeting platform and supply chain infrastructure highlighted as key differentiators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147032,"accession_number":"0000950170-25-093556","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation; no specific details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed a Form 8-K on July 3, 2025, referencing an updated corporate presentation.","The attached presentation was not fully provided, so no new metrics or milestones are available.","Investors should await further disclosure or contact the company for presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165567,"accession_number":"0000950170-25-088700","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA alignment opens third dosing cohort for Perspective's 212Pb-VMT-α-NET NET trial at 6 mCi (20% higher)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA opened Cohort 3 at 6 mCi (20% higher than Cohort 2) per dose for patients weighing >60 kg.","No DLTs observed among 42 patients treated; no grade ≥4 AEs; anti-tumor activity in 4 of 7 Cohort 2 DLT-evaluable patients.","Dosimetry sub-study using [203Pb]VMT-α-NET presented at SNMMI 2025 shows feasibility and tolerable absorbed doses.","Company on track to submit further clinical updates in 2H 2025, including longer safety and anti-tumor activity data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165566,"accession_number":"0000950170-25-080568","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics unveils updated corporate presentation with clinical progress","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Updated presentation highlights [212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors with sustained anti-tumor activity and tolerability.","Melanoma program [212Pb]VMT01 Phase 1/2a trial for metastatic melanoma includes TEAE safety data and trial design.","PSV359 Phase 1/2a trial targets FAP-α expression on tumor and stroma for multiple cancers.","Company describes pre-targeting platform and on-demand supply chain for regional radiopharmaceutical delivery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165565,"accession_number":"0000950170-25-079876","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET in NETs at ASCO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No dose-limiting toxicities, no discontinuations due to AEs, and no Grade 4/5 TEAEs in 42 treated patients.","Four of seven patients in Cohort 2 had objective responses per RECIST v1.1; three confirmed, one pending confirmation.","Seven of nine patients from Cohorts 1 and 2 remained progression-free after more than one year of follow-up.","Safety acceptable: low-grade hematologic toxicities; all creatinine increases Grade 1; no serious renal complications.","Cohort 2 re-opened in Aug 2024; 33 additional patients enrolled; company engaging FDA for further dose finding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165564,"accession_number":"0000950170-25-078439","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Perspective Therapeutics annual meeting results: all director nominees elected, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; Frank Morich received 35.4M for and 17.1M withheld (33% withhold).","Say-on-pay passed with 73.7% support (38.7M for, 13.7M against, 0.15M abstain), excluding 8.3M broker non-votes.","Ratification of WithumSmith+Brown as auditor approved with 59.1M for, 1.6M against, 0.14M abstain.","Quorum of 82.17% of 74,050,841 shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165563,"accession_number":"0000950170-25-069301","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics Q1 net loss $18.2M; VMT-α-NET cohort enrollment reaches 40 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.2M ($0.25 loss per share) vs $12.3M loss in prior year; R&D spend +92% to $14.3M.","Cash $212M as of March 31; expects funding into late 2026; sold $10.2M in ATM shares in Feb 2025 at ~$3.02/share.","VMT-α-NET: 40 patients enrolled in Cohort 2 as of April 30; data accepted for oral ASCO 2025 presentation.","VMT01: first patient treated at new monotherapy dose level (April 2025) and in combo with nivolumab (March 2025).","PSV359: first patient dosed; three new U.S. manufacturing sites underway for future commercial demand."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165562,"accession_number":"0000950170-25-061994","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation on 212Pb radiopharmaceutical pipeline","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Neuroendocrine tumor trial VMT-α-NET Phase 1/2a shows sustained anti-tumor activity and good tolerability; no renal function decline observed.","Metastatic melanoma program VMT01/02 Phase 1/2a dosing ongoing; treatment-emergent AEs summarized in presentation.","PSV359 Phase 1/2a targets FAP-α expression on tumor and stroma.","Platform uses proprietary chelator optimized for lead-212 RPTs and on-demand regional manufacturing infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165561,"accession_number":"0000950170-25-059557","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics doses first patient in Phase 1/2a trial of PSV359 for FAP-α positive solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed with [212Pb]PSV359 in Phase 1/2a dose-finding trial for FAP-α positive solid tumors.","Patients selected via SPECT imaging with [203Pb]PSV359 to identify FAP-α expression.","Trial aims to determine safety and preliminary anti-tumor activity; dose selection for monotherapy or combination.","PSV359 construct optimized for tumor uptake, retention, and fast clearance from healthy tissues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165560,"accession_number":"0000950170-25-053023","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics doses first patient in new 1.5 mCi monotherapy cohort for lead TAT candidate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1/2a trial of [212Pb]VMT01 as monotherapy at 1.5 mCi in MC1R-positive metastatic melanoma.","Cohort includes patients with brain metastases; prior imaging showed tracer uptake in brain lesions.","Combination arm with nivolumab began dosing in March 2025; Fast Track Designation from FDA granted September 2024.","Initial monotherapy results were presented at SMR October 2024; this cohort aims to refine dosing and assess brain metastasis activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183194,"accession_number":"0000950170-25-045227","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports FY2024 net loss $79.3M; cash $227M; VMT-α-NET enrollment reaches 30 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $79.3M ($1.23 loss per share) vs $46.5M in FY2023; R&D spend doubled to $41.6M.","Goodwill impairment of $24.1M due to low market cap; cash and investments $227M, funding expected into late 2026.","VMT-α-NET Phase 1/2a enrolled 30 patients in Cohort 2 as of Feb 2025; no DLTs, one confirmed response.","IND cleared for PSV359 (FAP-α targeting); first patient dosing expected mid-2025.","In Feb 2025, sold 3.38M shares under ATM at ~$3.02 for gross proceeds of $10.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183193,"accession_number":"0000950170-25-039826","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics doses first patient in [212Pb]VMT01 plus nivolumab combo cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed with [212Pb]VMT01 at 1.5 mCi in combination with nivolumab (Opdivo) for MC1R+ metastatic melanoma Phase 1/2a trial.","Earlier monotherapy cohorts showed no dose-limiting toxicities and early signs of anti-tumor activity, presented at SMR October 2024.","FDA granted Fast Track Designation for [212Pb]VMT01 in unresectable or metastatic melanoma with MC1R expression in September 2024.","New cohort explores dual mechanism of targeted alpha-particle therapy plus PD-1 blockade to improve patient outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183192,"accession_number":"0000950170-25-031324","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics updates corporate presentation highlighting pipeline progress and clinical data","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["[212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors shows anti-tumor activity with no renal decline.","Melanoma program [212Pb]VMT01 Phase 1/2a ongoing; safety profile detailed in presentation.","PSV359 targeting FAP-α active on tumor and stroma; pre-targeting platform also described.","On-demand order fulfillment at regional sites as part of supply chain and manufacturing infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183191,"accession_number":"0000950170-25-012317","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics posts updated corporate presentation; no specific material updates provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed current report on Form 8-K with an updated corporate presentation under Item 8.01.","Presentation covers business strategy, pipeline, and outlook; no new financial or operational disclosures.","No earnings, M&A, leadership, or other material event reported in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183190,"accession_number":"0000950170-25-008603","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET: 3 objective responses, no DLTs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three objective responses (1 confirmed, 2 unconfirmed) in Cohort 2 at 5.0 mCi dose; 5 stable disease; 1 progressive disease.","No dose-limiting toxicities, grade 4/5 events, or SAEs reported; hematologic AEs were grade 1-2 only.","Additional 11 patients dosed in Cohort 2 since August 2024, totaling 18 as of Dec 31, 2024.","Company pursuing dose escalation to Cohort 3 after FDA consultation; data submitted to FDA in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183189,"accession_number":"0000950170-25-004595","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports $227.8M cash, updates on VMT-α-NET and VMT01 trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents and ST investments: $227.8M as of Dec 31, 2024, funding operations into late 2026.","VMT-α-NET: 18 patients dosed in Cohort 2; data submitted to FDA; poster at ASCO-GI Jan 2025.","VMT01: SMC recommends 1.5 mCi dose as monotherapy and with nivolumab; both cohorts open for enrollment.","PSV359 IND filed late 2024; site activation underway, enrollment potentially mid-2025.","Four additional novel assets planned for first-in-human imaging in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183188,"accession_number":"0000950170-25-001712","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perspective Therapeutics appoints Juan Graham as CFO; Jonathan Hunt remains CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Juan Graham appointed CFO effective Jan 6, 2025; Jonathan Hunt steps down as CFO but stays CAO.","Graham brings 25 years experience; previously CFO of FibroGen, finance leadership at Johnson & Johnson.","Annual base salary $500k, target bonus 40%, signing bonus $80k, option grant of 400k shares with 4-year vest.","Severance: 12 months salary plus pro-rated bonus and COBRA upon termination without cause or for good reason.","Change of control: accelerated vesting of equity; severance of 12 months salary if not retained or termination within 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199781,"accession_number":"0000950170-24-133062","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics posts updated corporate presentation; no specific new facts disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company announced posting of an updated corporate presentation on its website on December 3, 2024.","Full content of the presentation was not included in this 8-K excerpt; no material updates are available from the filing text.","Investors should review the presentation directly at www.perspectivetherapeutics.com for any changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199780,"accession_number":"0000950170-24-129487","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports positive Phase 1/2a data for [212Pb]VMT-α-NET in NETs; pursuing dose escalation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No dose-limiting toxicities observed at 2.5 and 5.0 mCi doses; safety profile favorable.","Eight of nine patients had durable disease control; six of nine had measurable tumor reduction, one confirmed RECIST response.","Safety Monitoring Committee recommends dose escalation to Cohort 3; company to engage with FDA.","Plans to file IND for PSV359 (FAP-α targeting) by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199779,"accession_number":"0000950170-24-127384","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corporate presentation filed; content unavailable in exhibit text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed on November 15, 2024; ticker CATX on NYSE American.","Updated corporate presentation posted on company website and attached as Exhibit 99.1.","Exhibit text truncated; no specific financial, operational, or strategic details extractable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199778,"accession_number":"0000950170-24-125353","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perspective Therapeutics Q3 net loss $15.1M ($0.21/share); cash $267.8M funds into mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing and discontinued ops $15.1M vs $10.4M YoY; basic loss per share $0.21.","Cash, equivalents and short-term investments $267.8M (Sep 30, 2024) vs $9.2M at Dec 31, 2023.","R&D expense surged 114% to $12.0M; G&A expense up 56% to $7.0M; no product revenue.","Phase 1/2a trials advancing: VMT-α-NET and VMT01; combo cohort with nivolumab open.","Manufacturing capacity expanded: second cGMP facility in Somerset, NJ and three new buildings purchased."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199777,"accession_number":"0001193125-24-236468","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perspective Therapeutics reports Phase 1/2a data for [212Pb]VMT01; no dose-limiting toxicities observed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No dose-limiting toxicities; TEAEs mostly Grades 1–2; no renal toxicities reported despite high renal dosimetry.","At 3.0 mCi dose: 1 RECIST objective response, 2 patients with stable disease at 9 and 11 months.","At 5.0 mCi dose: patients progressed after first or second cycle; findings consistent with preclinical immunostimulatory effect at lower doses.","SMC recommends testing 1.5 mCi dose as monotherapy and in combination with nivolumab; combination cohort now enrolling.","Median 5 prior lines of therapy; FDA Fast Track Designation; plan to update on VMT-α-NET study by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215795,"accession_number":"0000950170-24-108407","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Perspective Therapeutics enters €49M equipment deal with Comecer for radiopharmaceutical production","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Agreement with Comecer SpA for manufacturing equipment including isotope processing hot cells and production suites.","Total consideration of approximately €49 million, payable in cash in installments; excludes taxes, customs, insurance.","Equipment to be installed at multiple U.S. production facilities; supports radiopharmaceutical product manufacturing.","Agreement includes representations, warranties, and termination provisions; company may also purchase additional equipment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215794,"accession_number":"0000950170-24-103731","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Fast Track Designation for Perspective's VMT01 in MC1R-positive melanoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Fast Track for 212Pb VMT01: diagnosis and treatment of unresectable or metastatic MC1R-positive melanoma.","Designation enables more frequent FDA interactions and eligibility for accelerated/priority/rolling review.","Phase 1/2a Cohort 2 DLT observation period completed; safety data to be shared with SMC and scientific forum.","Company plans to open VMT01/anti-PD-1 combination cohort pending IRB approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215793,"accession_number":"0000950170-24-102338","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Mark Austin departs; separation agreement provides $138K severance and COBRA subsidy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Austin ceased as executive officer and co-principal financial officer on Aug 16, 2024.","Separation agreement finalized Aug 26, 2024; Austin remains strategic advisor through Aug 30, 2024.","Severance includes $138,360.75 (6 months base salary) and $7,686.54 for COBRA coverage.","Payments conditional on signing release and compliance with separation terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215792,"accession_number":"0000950170-24-098685","cik":728387,"company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Perspective Therapeutics CFO Hunt becomes sole principal financial officer; VP Austin departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Austin ceased as VP of Finance, Corporate Controller, Corporate Secretary, and co-principal financial officer on August 16, 2024.","CFO Jonathan Hunt (age 57) now serves as sole principal financial officer and principal accounting officer.","No arrangements, family relationships, or interested transactions exist between Hunt and the company or its officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":478994005.6730769,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-19T23:59:59+00:00|215792"}